Synapse - Clinical and genomic characterization of bladder carcinomas with glandular phenotype

Clinical and genomic characterization of bladder carcinomas with glandular phenotype Journal Article

Authors:	Almassi, N.; Whiting, K.; Toubaji, A.; Lenis, A. T.; Jordan, E. J.; Won, H.; Regazzi, A. M.; Chen, Y. B.; Gopalan, A.; Sirintrapun, S. J.; Fine, S. W.; Tickoo, S. K.; Ostrovnaya, I.; Pietzak, E. J.; Cha, E. K.; Goh, A. C.; Donahue, T. F.; Herr, H. W.; Donat, S. M.; Dalbagni, G.; Bochner, B. H.; Teo, M. Y.; Funt, S. A.; Rosenberg, J. E.; Reuter, V. E.; Bajorin, D. F.; Solit, D. B.; Al-Ahmadie, H.; Iyer, G.
Article Title:	Clinical and genomic characterization of bladder carcinomas with glandular phenotype
Abstract:	PURPOSE To compare oncologic outcomes and genomic alteration profiles in patients with bladder and urachal adenocarcinoma, urothelial carcinoma (UC) with glandular differentiation, and UC, not otherwise specified (NOS) undergoing surgical resection, with emphasis on response to systemic therapy. METHODS We identified patients with bladder cancer with glandular variants who underwent surgical resection at Memorial Sloan Kettering from 1995 to 2018 (surgical cohort) and/or patients who had tumor sequencing using a targeted next-generation sequencing platform (genomics cohort). Pathologic complete and partial response rates to neoadjuvant chemotherapy (NAC) and recurrence-free and cancer-specific survival were measured. Alteration frequencies between histologic subtypes were compared. RESULTS Thirty-seven patients with bladder adenocarcinoma, 46 with urachal adenocarcinoma, 84 with UC with glandular differentiation, and 1,049 with UC, NOS comprised the surgical cohort. Despite more advanced disease in patients with bladder and urachal adenocarcinoma, no significant differences in recurrence or cancer-specific survival by histology were observed after adjusting for stage. In patients with UC with glandular differentiation, NAC resulted in partial (<= pT1N0) and complete (pT0N0) responses in 28% and 17%, respectively. Bladder and urachal adenocarcinoma genomic profiles resembled colorectal adenocarcinoma with frequent TP53, KRAS, and PIK3CA alterations while the genomic profile of UC with glandular differentiation more closely resembled UC, NOS. Limitations include retrospective nature of analysis and small numbers of nonurothelial histology specimens. CONCLUSION The genomic profile of bladder adenocarcinomas resembled colorectal adenocarcinomas, whereas UC with glandular differentiation more closely resembled UC, NOS. Differences in outcomes among patients with glandular bladder cancer variants undergoing surgical resection were largely driven by differences in stage. Cisplatin-based NAC demonstrated activity in UC with glandular differentiation, suggesting NAC should be considered for this histologic variant. (c) 2022 by American Society of Clinical Oncology
Keywords:	radical cystectomy; urothelial carcinoma; neoadjuvant chemotherapy; management; outcomes; urachal carcinoma; cancer; promoter mutations
Journal Title:	JCO Precision Oncology
Volume:	6
ISSN:	2473-4284
Publisher:	American Society of Clinical Oncology
Date Published:	2022-01-01
Start Page:	e2100392
Language:	English
ACCESSION:	WOS:000975488400005
DOI:	10.1200/po.21.00392
PROVIDER:	wos
PMCID:	PMC9249273
PUBMED:	35731998
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding author is MSK author Gopa Iyer-- Source: Wos